- UHRA Home
- Browsing by Author
Browsing by Author "Gaya, A.M."
Now showing items 1-2 of 2
-
A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas
Meyer, T.; Gaya, A.M.; Dancey, G.; Stratford, M.R.L.; Othman, S.; Sharma, S.; Wellsted, D.; Taylor, N.J.; Stirling, J.J.; Poupard, L.; Folkes, L.K.; Chan, P.S.; Pedley, R.B.; Chester, K.A.; Owen, K.; Violet, J.A.; Malaroda, A.; Green, A.J.; Buscombe, J.; Padhani, A.R.; Rustin, G.J.; Begent, R.H. (2009)Purpose: In preclinical models, radioimmunotherapy with 131I-A5B7 anti–carcinoembryonic antigen (CEA) antibody (131I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike ... -
Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown : an exploratory study
Gaya, A.M.; Daley, F.; Taylor, N. J.; Tozer, G.; Qureshi, U; Padhani, A.; Pedley, R. Barbara; Begent, R; Wellsted, D.; Stirling, J J; Rustin, G (2008)Combretastatin-A4-phosphate (CA4P) acts most effectively against immature tumour vasculature. We investigated whether histological angiogenic profile can explain the differential sensitivity of human tumours to CA4P, by ...